What ergothioneine is

Ergothioneine (EGT / ERGO) is a betaine derivative of histidine carrying one sulphur atom. It was first isolated in 1909 by the French pharmacist Charles Tanret from ergot fungus (Claviceps purpurea) — hence the name — and later found widely in edible mushrooms (golden oyster, shiitake, king oyster), some fermented foods and animal tissues. Humans cannot synthesise it and obtain it only from diet, which is how its dedicated transporter was discovered.

On the cosmetic raw-material side, commercial ergothioneine comes mainly from two routes: microbial fermentation (engineered yeast or E. coli, capable of high-purity L-form) and chemical synthesis (different cost structure — check optical configuration and residues). A third category is mushroom extract liquid, but the EGT content there is usually low, which suits a sourcing story rather than carrying the efficacy load. Always verify three things on purchase: CAS 497-30-3, INCI name ERGOTHIONEINE and the L-configuration, and require a COA with purity and impurity profile.

Physico-chemically it is a white to off-white crystalline powder, freely soluble in water, colourless, essentially odourless and reasonably heat-tolerant — three properties that matter a lot on the bench. Colourless means it does not tint the system the way astaxanthin or CoQ10 does; odourless means it avoids the sulphurous note glutathione can bring; water-soluble and stable means it can run in aqueous systems without special encapsulation. The trade-off is unit cost — it is among the most expensive antioxidant actives available, so formulation strategy is "low level plus strong synergy" rather than loading one ingredient.

Ingredient fact box

How it works, plainly

One sentence to hold on to: ergothioneine is not a more aggressive antioxidant, it is one that gets delivered where it is needed and lasts longer. Its differentiation runs along two lines — getting in, and staying put.

• Line one: it has a ticket. Studies report an organic cation transporter, OCTN1 (gene SLC22A4), on human cell membranes that actively imports ergothioneine. That is unusual among cosmetic antioxidants: most rely on passive diffusion, where the concentration gradient decides how much gets in, whereas ergothioneine is actively invited in. An important caveat: having a dedicated transporter does not mean stronger efficacy — it means the body has a specific uptake and retention mechanism for it. Verify on PubMed with "ergothioneine transporter", "OCTN1" and "SLC22A4".
• Line two: it does not consume itself. The sulphur in ergothioneine exists as thione/thiol tautomers, with the thione form dominating at physiological pH. That configuration makes it remarkably insensitive to auto-oxidation in water — it does not yellow in an open vessel the way vitamin C does, nor does its sulphur group oxidise to disulphide as readily as glutathione's. The practical benefit on the bench: aqueous systems hold up better over shelf life and active retention is easier to defend.
• It is a scavenger, not a repairman. The literature reports scavenging of hydroxyl radicals, singlet oxygen and peroxynitrite, plus chelation of metal ions such as copper and iron that catalyse oxidative chain reactions. Read it as lowering the day-to-day oxidative load around the eyes, not as reversing anything.
• An honest note on evidence strength. Ergothioneine shows antioxidant and photoprotective results in cell work and some human studies, but high-quality, large, eye-area-specific randomised human trials are limited, and vehicles, concentrations and assessment methods vary widely. Claims should read "helps reduce the look of tiredness and dullness around the eyes" or "provides antioxidant support" — never "treats", "repairs damage" or "reverses ageing".

A blunt note for sourcing: ergothioneine is expensive, and it is more economical to treat it as the fuse in the formula rather than the main ingredient — a low level covers antioxidant groundwork while the headline benefit is carried by retinoids, peptides or brightening actives. A brief that says "lead with ergothioneine, load it up" usually blows the budget for a modest gain in perceived performance.

Best-fitting formats

Use level and formulation notes (verify by bench trial)

Common reference level: a common reference range in cosmetics is ≈0.01%–1%, with eye care formulas typically landing at the lower end of that band — the reason being unit cost, together with the fact that in-vitro antioxidant activity is usually seen at very low concentrations. The actual level is set on the bench by format, target-market rules, stability data and the cost ceiling, converted against the purity and impurity profile on the supplier COA.

• Hold pH in a slightly acidic-to-neutral window. Keep it at 5.5–7.5. That range favours the thione configuration and overall stability; strongly acidic or alkaline conditions shift the tautomeric balance and charge state and need separate verification.
• Metal ions are the hidden killer. Copper and iron catalyse oxidation and shorten active life noticeably. Control metal residues from raw materials, process water and equipment contact surfaces, and where needed add a chelator such as disodium EDTA, checking its status in the target market.
• Dissolution and addition order. EGT dissolves readily in water, so pre-dissolve it in part of the water as a stock solution before adding to the water phase to avoid uneven dispersion in a thickened system. Uniformity at low levels comes from the stock-solution method, not from longer stirring.
• Temperature. It tolerates heat better than most antioxidants, but still add at the lowest practical process temperature and avoid prolonged heating or repeated re-heating.
• Packaging. Relatively stable as it is, still use light-protective packaging and control headspace oxygen; dropper or ampoule formats suit an expensive active better.
• Put the raw-material spec into the purchase order. State L-configuration, purity (commonly ≥98%), heavy-metal and microbial limits, and the identification method (HPLC / optical rotation), and require COA, stability data and technical dossier documents.
• Stability protocol. 40 °C for 3 months plus freeze–thaw and light exposure, with EGT retention measured as one of the release criteria. Appearance, odour and pH alone will not support a claim.

The figures above are common reference levels for eye care formulas; the actual use level is set by the formulation engineer based on dosage form, compatibility and target-market rules. Permitted use conditions, limits and labelling requirements differ by market — complete a compliance review for each destination before shipment. All descriptions here are general cosmetic applications and appearance or skin-feel statements, not medical advice or efficacy guarantees.

Compliance and market notes (verify per target market)

• China: first verify listing status and historical maximum use level in the Inventory of Existing Cosmetic Ingredients in China (2021 edition) (per the latest NMPA announcement), then complete general cosmetic filing under the Cosmetic Supervision and Administration Regulation or follow the route applicable to the claim category. Where claims such as "antioxidant" or "anti-wrinkle" appear in the efficacy-claim evaluation rules, the corresponding evaluation must be completed and its summary published. Classification and evaluation requirements follow the regulatory adviser's opinion.
• EU (EC) No 1223/2009: declare the ingredient and impurity profile accurately in the CPNP notification, PIF and CPSR, and complete the safety assessment; claims must meet the (EU) No 655/2013 common criteria (legal compliance, truthfulness, evidential support and so on). Note also that assessments in the food or novel-food domain follow a different route from cosmetic use and cannot be cross-applied.
• US MoCRA (2022): facility registration, product listing, safety substantiation, adverse-event reporting and record-keeping apply, with labelling under the FD&C Act and relevant 21 CFR provisions. Cosmetic ingredients and finished products generally do not undergo pre-market approval — never write "FDA approved". If a supplier cites a GRAS conclusion, confirm it covers cosmetic use, not food use.
• Claim red lines (all markets): never use medical or absolute wording such as "treats", "repairs damage", "reverses ageing", "medical" or "detox". On the Chinese site use appearance wording such as "帮助改善眼周疲惫与暗沉外观" or "提供抗氧化Support", and never imply it can replace sun protection or medicine.
• Japan / Korea / Middle East: each follows its own cosmetic or quasi-drug pathway with different boundaries and limits — verify per target market, and confirm listing status and label format before export.
• Recommended action: at project kick-off, give your regulatory adviser four items — ingredient, use level, dosage form and claim copy — for one upfront review; this costs an order of magnitude less than rewriting copy after production. Lock the origin route (fermentation or synthesis) and configuration at the same time to avoid being forced into a material change at scale.

Ingredient pairings

• Ergothioneine + vitamin C derivative (e.g. 3-O-ethyl ascorbic acid, 1%–3%): a dual aqueous antioxidant pair. Different redox potentials and different reactive species covered make this the most common water-phase combination in anti-ageing serums; confirm each one's pH and stability window.
• Ergothioneine + glutathione (0.1%–1%): two sulphur-containing antioxidants covering different redox tiers; note that glutathione oxidises readily and can bring a sulphurous note — verify odour and retention together.
• Ergothioneine + vitamin E (tocopherol, 0.5%–2%): a water-phase plus oil-phase antioxidant network suited to creams and oil serums, with vitamin E also protecting the oil phase from oxidative rancidity.
• Ergothioneine + niacinamide (2%–5%): antioxidant plus even tone plus barrier support — one of the most practical combinations for a "tired-looking eyes" brief.
• Ergothioneine + sodium hyaluronate (0.1%–0.5%) + panthenol (1%–3%): a hydrating, soothing base that improves periorbital tolerance, good for gentle daily-use anti-ageing lines.
• Use with care: avoid long-term coexistence with strong oxidisers and peroxide-based systems; avoid contamination by copper and iron (pipework, process water, pigments). Combining with high-level strong acids (such as AHAs) or alkaline systems needs separate pH and stability verification — split timing or split lines where necessary. Bottling alongside metal-ion actives such as copper peptides requires both compatibility and active-retention verification.

Formulation pairing cards

FAQ

Image briefs